Document is current

Article History

Received: 16 August 2022

Accepted: 25 November 2022

First Online: 29 December 2022

Declarations

:

: No ethic approval is needed due to the nature of this study.

: Not required.

: MP received research funding from Novartis and honoraria for lecturing from ArgenX, Biogen, Janssen and Merck. His research is founded by the German Multiple Sclerosis Society North Rhine-Westphalia (DMSG). LA no conflict of interest. LM received compensation for an educational internship at Biogen. AW no conflict of interest. LRN no conflict of interest. CN no conflict of interest. HL no conflict of interest. UM no conflict of interest. JS has received payments for advisory boards, speaker’s honoraria, travel expenses or research projects from Abcuro, Alnylam, Argenx, Biotest, CSL Behring, Euroimmun, Janssen, Kezar, LFB, Novartis, Octapharma and UCB. SGM received honoraria for lecturing and travel expenses for attending meetings from Almirall, Amicus Therapeutics Germany, Bayer Health Care, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi-Aventis, Chugai Pharma, QuintilesIMS, and Teva. His research is funded by the German Ministry for Education and Research (BMBF), Bundesinstitut für Risikobewertung (BfR), Deutsche Forschungsgemeinschaft (DFG), Else Kröner Fresenius Foundation, Gemeinsamer Bundesausschuss (G-BA), German Academic Exchange Service, Hertie Foundation, Interdisciplinary Center for Clinical Studies (IZKF) Muenster, German Foundation Neurology and by Alexion, Almirall, Amicus Therapeutics Germany, Biogen, Diamed, Fresenius Medical Care, Genzyme, HERZ Burgdorf, Merck Serono, Novartis, ONO Pharma, Roche, and Teva. TR reports grants from German Ministry of Education, Science, Research and Technology, grants and personal fees from Sanofi-Aventis and Alexion; personal fees from Biogen Idec, Roche and Teva; personal fees and nonfinancial support from Merck Serono, outside the submitted work.